- Home
- REGN
as 11-05-2025 4:00pm EST
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | TARRYTOWN |
| Market Cap: | 59.5B | IPO Year: | 1991 |
| Target Price: | $779.00 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 41.59 | EPS Growth: | 2.88 |
| 52 Week Low/High: | $476.49 - $844.51 | Next Earning Date: | 10-28-2025 |
| Revenue: | $14,247,800,000 | Revenue Growth: | 2.89% |
| Revenue Growth (this year): | 1.34% | Revenue Growth (next year): | 5.23% |
Stock Insider Trading Activity of Regeneron Pharmaceuticals Inc. (REGN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| POON CHRISTINE A | REGN | Director | Oct 29 '25 | Sell | $654.92 | 6,500 | $4,252,745.32 | 8,202 |
Latest Regeneron Pharmaceuticals Inc. News
REGN Breaking Stock News: Dive into REGN Ticker-Specific Updates for Smart Investing
Benzinga
a day ago
Michael Burry Is Super-Bearish On Palantir — With 5 Million Puts
StockStory
2 days ago
5 Revealing Analyst Questions From Regeneron’s Q3 Earnings Call
GlobeNewswire
3 days ago
Regeneron Announces Investor Conference Presentations
Motley Fool
3 days ago
2 Beaten-Down Stocks That Could Be About to Rally
Motley Fool
4 days ago
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%
MT Newswires
6 days ago
Regeneron Pharmaceuticals Insider Sold Shares Worth $4,252,745, According to a Recent SEC Filing
Simply Wall St.
6 days ago
Is OPKO’s Regeneron Deal and Asset Sale Shifting the Investment Case for OPKO Health (OPK)?
MT Newswires
6 days ago
Rothschild & Co Redburn Adjusts Price Target on Regeneron Pharmaceuticals to $910 From $900
Compare REGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "REGN Regeneron Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.